120 related articles for article (PubMed ID: 31502898)
21. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
22. BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
Maël H; Audrey B; Evelyne CB; Pierre-Yves D; Kaddour C; Gilles S; Arnaud P
Ann Hematol; 2017 Feb; 96(2):335-336. PubMed ID: 27761606
[No Abstract] [Full Text] [Related]
23. The current status of ponatinib in the treatment of chronic myeloid leukemia.
Deininger M
Clin Adv Hematol Oncol; 2014 May; 12(5):329-31. PubMed ID: 25003490
[No Abstract] [Full Text] [Related]
24. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.
Okabe S; Tauchi T; Tanaka Y; Katagiri S; Kitahara T; Ohyashiki K
Blood; 2013 Oct; 122(17):3086-8. PubMed ID: 24159169
[No Abstract] [Full Text] [Related]
25. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
26. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Wehrle J; von Bubnoff N
Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
[TBL] [Abstract][Full Text] [Related]
27. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.
Nazha A; Romo CG; Kantarjian H; Cortes J
Haematologica; 2013 Oct; 98(10):e131. PubMed ID: 24091930
[No Abstract] [Full Text] [Related]
28. Ariad Pharmaceutical's ninja cancer drug inhibits armies of mutants.
Wolfson W
Chem Biol; 2012 Sep; 19(9):1075-6. PubMed ID: 22999871
[No Abstract] [Full Text] [Related]
29. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
Shibata N; Shimokawa K; Nagai K; Ohoka N; Hattori T; Miyamoto N; Ujikawa O; Sameshima T; Nara H; Cho N; Naito M
Sci Rep; 2018 Sep; 8(1):13549. PubMed ID: 30202081
[TBL] [Abstract][Full Text] [Related]
31. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
Curik N; Laznicka A; Polivkova V; Krizkova J; Pokorna E; Semerak P; Suchankova P; Burda P; Hochhaus A; Machova Polakova K
Leukemia; 2024 Jun; 38(6):1415-1418. PubMed ID: 38615117
[No Abstract] [Full Text] [Related]
32. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
33. [Chronic myeloid leukemia].
Tojo A
Nihon Rinsho; 2012 Nov; 70 Suppl 8():501-7. PubMed ID: 23513891
[No Abstract] [Full Text] [Related]
34. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
Boo YL; Liam CCK; Toh SG; Lim SM
Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
[No Abstract] [Full Text] [Related]
35. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
36. Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.
Dufies M; Cassuto O; Jacquel A; Robert G; Auberger P
Cell Cycle; 2013 Jun; 12(11):1645-6. PubMed ID: 23673326
[No Abstract] [Full Text] [Related]
37. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
[TBL] [Abstract][Full Text] [Related]
38. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
[TBL] [Abstract][Full Text] [Related]
39. Where exactly does ponatinib fit in chronic myelogenous leukemia?
Berman E
J Natl Compr Canc Netw; 2014 Nov; 12(11):1615-20. PubMed ID: 25361807
[TBL] [Abstract][Full Text] [Related]
40. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
